BioLine Rx(BLRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BLRX BioLine Rx

Post-Mkt 12-11 18:46:40 EST

3.23

-0.08

-2.42%

盘后3.28

+0.05+1.55%

16:10 EST

High3.29	Low3.16	Vol14.94K
Open3.26	D1 Closing3.31	Amplitude3.93%
Mkt Cap14.05M	Tradable Cap13.48M	Total Shares4.35M
T/O48.12K	T/O Rate0.36%	Tradable Shares4.17M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BLRX","market":"US","secType":"STK","nameCN":"BioLine Rx","latestPrice":3.23,"timestamp":1765486800000,"preClose":3.31,"halted":0,"volume":14943,"hourTrading":{"tag":"盘后","latestPrice":3.28,"preClose":3.23,"latestTime":"16:10 EST","volume":58,"amount":190.23999999999998,"timestamp":1765487404151},"delay":0,"floatShares":4173500,"shares":4351357,"eps":-0.8394,"marketStatus":"Post-Mkt","change":-0.08,"latestTime":"12-11 18:46:40 EST","open":3.26,"high":3.29,"low":3.16,"amount":48118.2962,"amplitude":0.039275,"askPrice":3.32,"askSize":48,"bidPrice":2.82,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.8394,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1765501200000},"marketStatusCode":4,"adr":0,"adrRate":600,"exchange":"NASDAQ","adjPreClose":3.31,"preHourTrading":{"tag":"盘前","latestPrice":3.31,"preClose":3.31,"latestTime":"08:00 EST","volume":50,"amount":165.5,"timestamp":1765458001810},"postHourTrading":{"tag":"盘后","latestPrice":3.28,"preClose":3.23,"latestTime":"16:10 EST","volume":58,"amount":190.23999999999998,"timestamp":1765487404151},"volumeRatio":0.51196,"impliedVol":0.4987,"impliedVolPercentile":0.2249},"requestUrl":"/m/hq/s/BLRX/tweets","defaultTab":"tweets","newsList":[{"id":"2586141372","title":"BioLine Rx Q3 EPADS $(0.22) Beats $(1.20) Estimate, Sales $427.000K Miss $990.000K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2586141372","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586141372?lang=en_us&edition=fundamental","pubTime":"2025-11-25 06:36","pubTimestamp":1764023799,"startTime":"0","endTime":"0","summary":"BioLine Rx (NASDAQ:BLRX) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(1.20) by 81.67 percent. This is a 214.29 percent decrease over losses of $(0.07) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/49046801/bioline-rx-q3-epads-0-22-beats-1-20-estimate-sales-427-000k-miss-990-000k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"BioLine Rx Q3 EPADS $(0.22) Beats $(1.20) Estimate, Sales $427.000K Miss $990.000K Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLRX"],"gpt_icon":0},{"id":"2586842497","title":"Analysts Are Bullish on Top Healthcare Stocks: Bioline RX Ltd Sponsored ADR (BLRX), Ocular Therapeutix (OCUL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2586842497","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586842497?lang=en_us&edition=fundamental","pubTime":"2025-11-25 04:00","pubTimestamp":1764014448,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Bioline RX Ltd Sponsored ADR (BLRX – Research Report...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-bioline-rx-ltd-sponsored-adr-blrx-ocular-therapeutix-ocul-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-bioline-rx-ltd-sponsored-adr-blrx-ocular-therapeutix-ocul-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4007","XBI","XLV","BK4588","OCUL","BK4137","BLRX","HCSG","BK4585","LABU","LU0029874061.USD","BK4112","LU0128526141.USD","BK4581"],"gpt_icon":0},{"id":"2585746149","title":"Israeli biopharma BioLineRx's Q3 loss narrows as costs drop","url":"https://stock-news.laohu8.com/highlight/detail?id=2585746149","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585746149?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:17","pubTimestamp":1763986641,"startTime":"0","endTime":"0","summary":"Israeli biopharma BioLineRx's Q3 loss narrows as costs dropOverviewBioLineRx reports Q3 net loss of $1 mln, narrower than $5.8 mln loss in year-ago quarterCompany says joint venture plan with Hemisphe","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nL1N3X00A8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLRX","BK4139"],"gpt_icon":0},{"id":"2585658461","title":"Press Release: BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2585658461","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585658461?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:00","pubTimestamp":1763985600,"startTime":"0","endTime":"0","summary":"- Establishes joint venture with Hemispherian AS to advance GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other cancers -. - Phase 1/2a clinical trial of GLIX1 expected to commence in Q1 2026 -. - Management to host conference call today, November 24 , at 8:30 am EST -. TEL AVIV, Israel, Nov. 24, 2025 /PRNewswire/ -- BioLineRx Ltd.  , a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the quarter ended September 30, 2025, and provided a corporate update.\"At the same time, the ongoing CheMo4METPANC Phase 2b clinical trial of motixafortide in metastatic pancreatic cancer, which is being led by Columbia University and supported by both Regeneron and BioLineRx, continues to progress, giving us a second opportunity to leverage our drug development expertise to bring true innovation to patients with difficult-to-treat cancers,\" Mr. Se","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","LU2413666426.HKD","BK4567","BK4533","PB","BK4211","LU1093756325.SGD","LU1721428933.USD","BK4588","IE00BYQQ9H92.USD","BK4139","BK4548","IE00BLDYK493.USD","LU0347712357.USD","BLRX","BK4121","LU1093756168.USD","ASH","MTD","LU2211817866.USD","IE00B64QTZ34.USD","BK4109","SCD","PFS","BK4585","LU2413666699.HKD","IE00BFXG0V08.USD","LU2463526074.USD"],"gpt_icon":0},{"id":"2585657894","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2585657894","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585657894?lang=en_us&edition=fundamental","pubTime":"2025-11-24 19:00","pubTimestamp":1763982000,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Blue Bird Corp                                  4Q      1.05   3:01 PM. ·Cntrl Gdn & Pet                                 4Q      (.20)      AMC. ·Anavex Life Scncs                               4Q      (.15)  7:30 AM. ·Best Buy Co. Inc.                                3Q      1.31       BMO. ·Dick's Sprting Gds                               3Q      2.69   7:00 AM","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAAP","DOOO","AMTM","BBW","EMBC","LI","ZM","CLFD","SLP","GCO","BLBD","AVXL","SJM","SYM","NTAP","CENT","ZS","PD","BLRX","KR","GGAL","BURL","CLSK","NTNX","ARWR","A","AMBA","BBAR","KSS","CMBT","PFLT","BABA","BBY","ADI","DELL","SMTC","ANF","KEYS","NIO","DKS","FLNC","CRDO","HAFN","ADSK","DE","MDB","ATAT","HPQ","CENTA","NAT"],"gpt_icon":0},{"id":"2584338941","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2584338941","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584338941?lang=en_us&edition=fundamental","pubTime":"2025-11-20 19:00","pubTimestamp":1763636400,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Jacobs Solutions Inc.                              4Q      1.68   6:45 AM. ·ZIM Integrated Shpg                              3Q       .77   7:00 AM","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESTC","AZTA","ADSK","DRTS","MOG.B","ALLT","CAL","BBWI","BURL","CMBT","CLCO","AUNA","GAP","ARWR","NTES","FLNC","ANF","DLTR","ATAT","DE","AMBA","VIPS","ZM","FRO","CDLR","A","BULL","ADI","CPRT","CENT","ATKR","BLBD","CENTA","EMBC","GGAL","FIVE","AMTM","DKS","ZS","BJ","CLFD","BBY","BBW","DELL","DOOO","WMT","BBAR","BLRX"],"gpt_icon":1},{"id":"2559685859","title":"UPDATE: BioLine Rx Q2 EPADS $(1.00) Beats $(1.20) Estimate, Sales $304.000K Miss $924.000K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2559685859","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559685859?lang=en_us&edition=fundamental","pubTime":"2025-08-14 22:12","pubTimestamp":1755180740,"startTime":"0","endTime":"0","summary":"BioLine Rx (NASDAQ:BLRX) reported quarterly losses of $(1.00) per share which beat the analyst consensus estimate of $(1.20) by 16.67 percent.  The company reported quarterly sales of $304.000 thousand which missed the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/47124175/update-bioline-rx-q2-epads-1-00-beats-1-20-estimate-sales-304-000k-miss-924-000k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLRX"],"gpt_icon":0},{"id":"2559959755","title":"BioLineRx Had Cash, Cash Equivalents, And Short-term Bank Deposits Of $28.2M, Sufficient To Fund Operations, As Currently Planned, Into 1H Of 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2559959755","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559959755?lang=en_us&edition=fundamental","pubTime":"2025-08-14 19:03","pubTimestamp":1755169398,"startTime":"0","endTime":"0","summary":"BioLineRx Had Cash, Cash Equivalents, And Short-term Bank Deposits Of $28.2M, Sufficient To Fund Operations, As Currently Planned, Into 1H Of 2027","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/general/biotech/25/08/47117520/biolinerx-had-cash-cash-equivalents-and-short-term-bank-deposits-of-28-2m-sufficient-to-fund-oper","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLRX","BK4139"],"gpt_icon":0},{"id":"2559195929","title":"BioLine Rx Q2 2025 EPS $(0.00) Beats $(1.20) Estimate, Sales $304.000K Miss $924.000K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2559195929","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559195929?lang=en_us&edition=fundamental","pubTime":"2025-08-14 19:02","pubTimestamp":1755169325,"startTime":"0","endTime":"0","summary":"BioLine Rx Q2 2025 EPS $(0.00) Beats $(1.20) Estimate, Sales $304.000K Miss $924.000K Estimate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/47117503/bioline-rx-q2-2025-eps-0-00-beats-1-20-estimate-sales-304-000k-miss-924-000k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLRX"],"gpt_icon":0},{"id":"2558642134","title":"BioLine RX Ltd  expected to post a loss of 53 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2558642134","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558642134?lang=en_us&edition=fundamental","pubTime":"2025-08-12 20:44","pubTimestamp":1755002644,"startTime":"0","endTime":"0","summary":"BioLine RX Ltd  expected to post a loss of53cents a share - Earnings Preview BioLine RX Ltd BLRX.OQ, BLRX.O is expected to  show a fall in quarterly revenue when it reports  results on August 14 for t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nL8N3U40VQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLRX"],"gpt_icon":0},{"id":"2544961068","title":"BioLine RX Price Target Maintained With a $26.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2544961068","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544961068?lang=en_us&edition=fundamental","pubTime":"2025-06-17 19:29","pubTimestamp":1750159740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BLRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 17, 2025 07:29 ET (11:29 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLRX"],"gpt_icon":0},{"id":"2539220685","title":"BioLine RX Raised to Buy From Hold by Jones Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2539220685","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539220685?lang=en_us&edition=fundamental","pubTime":"2025-05-30 21:26","pubTimestamp":1748611560,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BLRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 30, 2025 09:26 ET (13:26 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLRX"],"gpt_icon":0},{"id":"2539654224","title":"Bioline Says Pilot Study of Potential Pancreatic Cancer Drug Combo Shows Improved Overall Response Rate; Shares Soar Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2539654224","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539654224?lang=en_us&edition=fundamental","pubTime":"2025-05-30 20:00","pubTimestamp":1748606407,"startTime":"0","endTime":"0","summary":"Bioline RX  said Friday that results from a pilot phase 2 clinical trial of its drug motixafortide, along with cemiplimab and standard-of-care chemotherapies, as a first-line treatment for pancreatic cancer showed that four out of 11 patients remained progression-free after more than one year.The study is evaluating the motixafortide combination against gemcitabine and nab-paclitaxel alone, the company said.An analysis also revealed that tumor infiltration increased in all eleven patients treated with the motixafortide combination, the company said.In all, the trial showed an overall response rate of 64% and a disease control rate of 91%, compared to historical rates of 23% and 48%, respectively, for gemcitabine and nab-paclitaxel, the company said.The company said the trial will now increase enrollment in a randomized study to 108, from the previous 30, by 2027.Shares of the company were up more than 64% in recent premarket activity.Price: 6.25, Change: +2.46, Percent Change: +64.87","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BLRX"],"gpt_icon":0},{"id":"2539221688","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2539221688","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539221688?lang=en_us&edition=fundamental","pubTime":"2025-05-30 19:30","pubTimestamp":1748604623,"startTime":"0","endTime":"0","summary":"BioLineRx  shares were 99% higher pre-bell Friday after the company said updated results from a phase 2 trial of motixafortide in pancreatic cancer showed four of 11 patients remained progression free after more than one year.Bolt Projects Holdings  stock was up 90%, reversing from Thursday's slide.Red Robin Gourmet Burgers  shares were 32% higher after the company reported late Thursday it swung to fiscal Q1 adjusted earnings amid higher revenue.LZ Technology Holdings  stock was up 18%, extending Thursday's rally.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BLRX","RRGB","BSLK","LZMH","BK4009","BK4090","BK4209"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.biolinerx.com","stockEarnings":[{"period":"1week","weight":0.028},{"period":"1month","weight":-0.0378},{"period":"3month","weight":-0.1746},{"period":"6month","weight":-0.2942},{"period":"1year","weight":-0.6532},{"period":"ytd","weight":-0.6133}],"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":0.009},{"period":"3month","weight":0.0455},{"period":"6month","weight":0.1517},{"period":"1year","weight":0.1406},{"period":"ytd","weight":0.1732}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.","yearOnYearQuotes":[{"month":1,"riseRate":0.642857,"avgChangeRate":0.068634},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.044107},{"month":3,"riseRate":0.214286,"avgChangeRate":-0.096578},{"month":4,"riseRate":0.357143,"avgChangeRate":-0.031516},{"month":5,"riseRate":0.571429,"avgChangeRate":0.094079},{"month":6,"riseRate":0.357143,"avgChangeRate":-0.031443},{"month":7,"riseRate":0.5,"avgChangeRate":0.025637},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.055209},{"month":9,"riseRate":0.4,"avgChangeRate":-0.015821},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.018467},{"month":11,"riseRate":0.266667,"avgChangeRate":-0.053503},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.059564}],"exchange":"NASDAQ","name":"BioLine Rx","nameEN":"BioLine Rx"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BioLine Rx(BLRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest BioLine Rx(BLRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"BioLine Rx,BLRX,BioLine Rx股票,BioLine Rx股票老虎,BioLine Rx股票老虎国际,BioLine Rx行情,BioLine Rx股票行情,BioLine Rx股价,BioLine Rx股市,BioLine Rx股票价格,BioLine Rx股票交易,BioLine Rx股票购买,BioLine Rx股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BioLine Rx(BLRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest BioLine Rx(BLRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction